Evaluation and treatment of Cushing's syndrome

被引:111
作者
Nieman, LK [1 ]
Ilias, I [1 ]
机构
[1] NICHHD, CRC, Reprod Biol & Med Branch, NIH, Bethesda, MD 20892 USA
关键词
pituitary neoplasms; adrenal gland neoplasms; Cushing's syndrome;
D O I
10.1016/j.amjmed.2005.01.059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cushing's syndrome results from sustained pathologic hypercortisolism caused by excessive corticotropin (ACTH) secretion by tumors in the pituitary gland (Cushing's disease, 70%) or elsewhere (15%), or by ACTH-independent cortisol secretion from adrenal tumors (15%). The clinical features are variable, and no single pattern is seen in all patients. Those features most specific for Cushing's syndrome include abnormal fat distribution, particularly in the supraclavicular and temporal fossae, proximal muscle weakness, wide purple striae, and decreased linear growth with continued weight gain in a child. Patients with characteristics Of glucocorticoid excess should be screened with measurements of saliva or urine cortisol or dexamethasone Suppression testing. The diagnosis of Cushing's syndrome should be followed by the measurement of plasma ACTH concentration to determine whether the hypercortisolism is ACTH-independent. In ACTH-dependent patients, bilateral inferior petrosal sinus sampling with measurement of ACTH before and after administration of ACTH-releasing hormone most accurately distinguishes pituitary from ectopic ACTH secretion. Surgical resection Of tumor is the optimal treatment for all forms Of Cushing's syndrome; bilateral adrenalectomy, medical treatment, or radiotherapy are sought in inoperable or recurrent cases. The medical treatment of choice is ketoconazole. The prognosis is better for Cushing's disease and benign adrenal causes Of Cushing's syndrome than adrenocortical cancer and malignant ACTH-producing tumors. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1340 / 1346
页数:7
相关论文
共 101 条
[1]  
AHLMAN H, 1993, EUR J SURG, V159, P149
[2]   Management of adrenocortical carcinoma [J].
Allolio, B ;
Hahner, S ;
Weismann, D ;
Fassnacht, M .
CLINICAL ENDOCRINOLOGY, 2004, 60 (03) :273-287
[3]   Cushing syndrome due to ectopic adrenocorticotropic hormone secretion [J].
Aniszewski, JP ;
Young, WF ;
Thompson, GB ;
Grant, CS ;
van Heerden, JA .
WORLD JOURNAL OF SURGERY, 2001, 25 (07) :934-940
[4]  
[Anonymous], 2001, CURR PROB SURG, V38, P488
[5]   Diagnosis and complications of Cushing's syndrome: A consensus statement [J].
Arnaldi, G ;
Angeli, A ;
Atkinson, AB ;
Bertagna, X ;
Cavagnini, F ;
Chrousos, GP ;
Fava, GA ;
Findling, JW ;
Gaillard, RC ;
Grossman, AB ;
Kola, B ;
Lacroix, A ;
Mancini, T ;
Mantero, F ;
Newell-Price, J ;
Nieman, LK ;
Sonino, N ;
Vance, ML ;
Giustina, A ;
Boscaro, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (12) :5593-5602
[6]   Effectiveness versus efficacy: The limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome [J].
Aron, DC ;
Raff, H ;
Findling, JW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (06) :1780-1785
[7]  
Ayala AR, 2003, CURR OPIN ENDOCRINOL, V10, P272, DOI DOI 10.1097/00060793-200308000-00008
[8]   Intermittent Cushing's disease in hirsute women [J].
BalsPratsch, M ;
Hanker, JP ;
Hellhammer, DH ;
Ludecke, DK ;
Schlegel, W ;
Schneider, HPG .
HORMONE AND METABOLIC RESEARCH, 1996, 28 (02) :105-110
[9]   Assessment of cure and recurrence after pituitary surgery for Cushing's disease [J].
Barbetta, L ;
Dall'Asta, C ;
Tomei, G ;
Locatelli, M ;
Giovanelli, M ;
Ambrosi, B .
ACTA NEUROCHIRURGICA, 2001, 143 (05) :477-482
[10]   Overnight dexamethasone suppression test: Comparison of plasma and salivary cortisol measurement for the screening of Cushing's syndrome [J].
Barrou, Z ;
Guiban, D ;
Maroufi, A ;
Fournier, C ;
Dugue, MA ;
Luton, JP ;
Thomopoulos, P .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1996, 134 (01) :93-96